# A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

> **NCT06444451** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 166 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** Amlitelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06444451
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-06
- **Primary completion:** 2025-09-24
- **Final completion:** 2028-01-05
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06444451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06444451, "A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06444451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*